​

Arcutis Biotherapeutics Ownership | Who Owns Arcutis Biotherapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Arcutis Biotherapeutics Ownership Summary

Arcutis Biotherapeutics is owned by 102.05% institutional investors, 1.76% insiders. Suvretta capital management is the largest institutional shareholder, holding 9.61% of ARQT shares. Polar Capital Biotech S Inc is the top mutual fund, with 4.28% of its assets in Arcutis Biotherapeutics shares.

ARQT Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockArcutis Biotherapeutics102.05%1.76%-3.81%
SectorHealthcare Stocks 35.49%11.75%52.76%
IndustryBiotech Stocks 34.83%11.71%53.46%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Suvretta capital management12.33M9.61%$290.42M
Blackrock8.62M7.76%$80.19M
Frazier life sciences management9.87M7.70%$232.64M
Blackrock funding, inc. /de9.20M7.17%$216.76M
Rubric capital management lp8.27M6.45%$194.88M
Vanguard group7.25M5.68%$210.65M
State street6.30M4.91%$148.34M
Polar capital5.67M4.42%$133.51M
Jennison associates4.98M3.88%$117.35M
Gilder gagnon howe4.30M3.36%$101.40M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Pivotal bioventure partners investment advisor1.36M11.42%$31.94M
Suvretta capital management12.33M7.42%$290.42M
Frazier life sciences management9.87M5.99%$232.64M
Ally bridge group (ny)233.22K2.68%$4.40M
Rubric capital management lp8.27M2.06%$194.88M
Stempoint capital lp413.79K1.89%$9.75M
Patient square capital lp400.64K1.67%$9.44M
Privium fund management b.v.320.97K1.57%$7.56M
Bioimpact capital733.97K1.34%$17.29M
Tejara capital166.19K1.29%$3.92M

Top Buyers

HolderShares% AssetsChange
Marshall wace, llp2.43M0.06%1.98M
Blackrock8.62M0.00%1.96M
State street6.30M0.01%807.90K
Vanguard fiduciary trust771.76K0.00%771.76K
Squarepoint ops1.10M0.03%647.61K

Top Sellers

HolderShares% AssetsChange
Jennison associates4.98M0.08%-1.78M
Paradigm biocapital advisors lp---1.47M
Perceptive advisors---1.36M
Braidwell lp---1.30M
Bain capital life sciences investors---1.03M

New Positions

HolderShares% AssetsChangeValue
Vanguard fiduciary trust771.76K0.00%771.76K$18.18M
M&g469.08K0.06%469.08K$11.26M
Adage capital partners gp366.00K0.01%366.00K$8.62M
Penn capital management company333.13K0.61%333.13K$7.86M
Peregrine capital management306.27K0.27%306.27K$7.22M

Sold Out

HolderChange
Clearstead advisors-20.00
Nelson, van denburg & campbell wealth management group-22.00
Stephens consulting-25.00
Golden state wealth management-59.00
Amundi-66.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2026270-6.90%129,847,5480.58%1021.00%141-19.43%8611.69%
Dec 31, 2025127-48.79%34,362,908-72.69%260.27%72-40.98%38-54.22%
Sep 30, 202587-63.14%29,200,444-76.92%220.23%44-63.64%25-62.69%
Jun 30, 2025234-6.02%126,474,0751.16%991.01%120-6.25%66-20.48%
Mar 31, 202524613.36%124,963,282-3.01%990.92%12716.51%8122.73%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Polar Capital Biotech S Inc5.36M4.28%355.94K
State Street® SPDR® S&P® Biotech ETF3.83M3.06%-37.92K
Vanguard US Total Market Shares ETF3.59M3.03%492.10K
Vanguard Total Stock Mkt Idx Inv3.51M2.83%51.52K
iShares Russell 2000 ETF2.59M2.07%21.81K
Jennison Health Sciences Equity2.27M1.90%-
PGIM Jennison Health Sciences Z2.27M1.89%-
SPDR® S&P Biotech ETF1.88M1.57%4.20K
PGIM Jennison Small Company A1.74M1.40%-403.71K
Jennison SMid Cap Core Equity1.59M1.28%-554.10K

Recent Insider Transactions

DateNameRoleActivityValue
May 11, 2026Vairavan Latha SVP Chief Financial OfficerSell$9.16K
May 11, 2026Burnett Patrick See RemarksSell$4.67K
May 04, 2026Matsuda Masaru See RemarksSell$20.87K
May 04, 2026Matsuda Masaru See RemarksSell$171.54K
May 04, 2026Burnett Patrick See RemarksSell$16.15K

Insider Transactions Trends

DateBuySell
2026 Q2-9
2026 Q1-26
2025 Q4-32
2025 Q3-15
2025 Q2910

ARQT Ownership FAQ

Who Owns Arcutis Biotherapeutics?

Arcutis Biotherapeutics shareholders are primarily institutional investors at 102.05%, followed by 1.76% insiders and -3.81% retail investors. The average institutional ownership in Arcutis Biotherapeutics's industry, Biotech Stocks , is 34.83%, which Arcutis Biotherapeutics exceeds.

Who owns the most shares of Arcutis Biotherapeutics?

Arcutis Biotherapeutics’s largest shareholders are Suvretta capital management (12.33M shares, 9.61%), Blackrock (8.62M shares, 7.76%), and Frazier life sciences management (9.87M shares, 7.70%). Together, they hold 25.08% of Arcutis Biotherapeutics’s total shares outstanding.

Does Blackrock own Arcutis Biotherapeutics?

Yes, BlackRock owns 7.76% of Arcutis Biotherapeutics, totaling 8.62M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 80.19M$. In the last quarter, BlackRock increased its holdings by 1.96M shares, a 29.49% change.

Who is Arcutis Biotherapeutics’s biggest shareholder by percentage of total assets invested?

Pivotal bioventure partners investment advisor is Arcutis Biotherapeutics’s biggest shareholder by percentage of total assets invested, with 11.42% of its assets in 1.36M Arcutis Biotherapeutics shares, valued at 31.94M$.

Who is the top mutual fund holder of Arcutis Biotherapeutics shares?

Polar Capital Biotech S Inc is the top mutual fund holder of Arcutis Biotherapeutics shares, with 4.28% of its total shares outstanding invested in 5.36M Arcutis Biotherapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools